Comparing ASK0912 to polymyxin B for hospital-acquired pneumonia
Part of Infections, Lungs & breathing clinical trials.
This study compares an experimental antibiotic called ASK0912 with an approved antibiotic (polymyxin B) in adults with hospital-acquired or ventilator-associated pneumonia. It aims to see if the new drug is as effective and safe as the standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have pneumonia that started during a hospital stay or while on a breathing machine.
- You have at least one symptom of pneumonia (like fever, cough, or difficulty breathing) and at least one abnormal lab test (like high white blood cell count).
- A chest X-ray or CT scan shows new or worsening signs of pneumonia.
- You are not allergic to polymyxin or carbapenem antibiotics.
- You have not received antibiotics for this pneumonia for more than 24 hours in the last 3 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new antibiotic (BV100 plus low-dose polymyxin B) against a standard treatment for pneumonia caused by a hard-to-treat bacteria (Acinetobacter baumannii). If you have hospital-acquired or ventilator-associated pneumonia and standard antibiotics aren't working, this study may offer a new option.
This study tests a new antibiotic called YK-1169 against a standard treatment for pneumonia that develops during a hospital stay or while on a breathing machine. It aims to see if the new drug works just as well or better.
This study tests whether a new antibiotic (BV100) combined with other antibiotics works safely and effectively against serious infections caused by drug-resistant Acinetobacter bacteria. It may offer a treatment option when standard antibiotics are not working.
This trial tests a combination of two antibiotics (meropenem and pralurbactam) for treating serious infections caused by bacteria that are resistant to many other antibiotics. It may be an option for hospitalized patients with pneumonia, urinary tract infections, abdominal infections, or bloodstream infections.
This trial tests a drug called Polymyxin E2 Methanesulfonate for a serious lung infection that patients can get in the hospital, caused by bacteria that don't respond to common antibiotics. It may be an option for people on ventilators or recently hospitalized with pneumonia that standard drugs can't treat.
This study looks at two strong antibiotics, polymyxin B and colistin, given through a vein to treat serious infections like pneumonia or blood infections caused by bacteria that are resistant to many other antibiotics. The goal is to see how well they work and how safe they are.
Hear when a new Ventilator-associated Bacterial Pneumonia (VABP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.